Immunophenotypic markers in adult acute lymphoblastic leukemia: the prognostic significance of CD20 and TdT expression.

Publisher: Springer Nature Country of Publication: Korea (South) NLM ID: 101605247 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2287-979X (Print) Linking ISSN: 2287979X NLM ISO Abbreviation: Blood Res Subsets: PubMed not MEDLINE

Publication: 2024- : [Cham, Switzerland] : Springer Nature
Original Publication: Seoul : Korean Society of Hematology

Background: Efforts to overcome poor outcomes in patients with adult acute lymphoblastic leukemia (ALL) have focused on combining new therapeutic agents targeting immunophenotypic markers (IPMs) with classical cytotoxic agents; therefore, it is important to evaluate the clinical significance of IPMs.
Methods: Baseline characteristics and clinical outcomes of patients with adult ALL were retrospectively analyzed. The percentage of blasts expressing IPMs at diagnosis was measured by multicolor flow cytometry analysis. Samples in which ≥20% of blasts expressed an IPM were considered positive.
Results: Among the total patient population (N=230), almost all (92%) were in first or second hematological complete remission (HCR) and 54% received allogeneic hematopoietic cell transplant (allo-HCT). Five-year hematologic relapse-free survival (HRFS) and overall survival (OS) rates were 36% and 39%, respectively, and 45.6% and 80.5% of patients were positive for the IPMs CD20 and terminal deoxynucleotidyl transferase (TdT), respectively. Expression of CD20, CD13, CD34, and TdT was associated with HRFS rate, and expression of CD20 and CD13 was associated with OS rate, as was the performance of allo-HCT. In multivariate analysis, positivity for CD20 (HRFS: hazard ratio [HR], 2.21, P<0.001; OS: HR, 1.63, P=0.015) and negativity for TdT (HRFS: HR, 2.30, P=0.001) were both significantly associated with outcomes. When patients were categorized into three subgroups according to positivity for CD20 and TdT, there were significant differences in HRFS and OS among the subgroups.
Conclusion: Positivity for CD20 and TdT expression and clinical risk group were prognostic factors in adult ALL.

Haematologica. 2010 Feb;95(2):324-8. (PMID: 19773266)
Cancer. 2006 Oct 1;107(7):1551-61. (PMID: 16955505)
Blood. 1991 Dec 1;78(11):2814-22. (PMID: 1835410)
Blood. 2014 Feb 6;123(6):843-50. (PMID: 24277073)
Leuk Res. 1987;11(6):537-43. (PMID: 3474480)
Blood. 2009 Jun 18;113(25):6330-7. (PMID: 18703706)
Leukemia. 2009 Oct;23(10):1763-70. (PMID: 19440217)
Blood. 2006 Nov 15;108(10):3302-4. (PMID: 16896151)
Am J Hematol. 2015 Nov;90(11):1013-20. (PMID: 26228525)
Blood. 2010 Sep 23;116(12):2070-7. (PMID: 20466853)
Am J Hematol. 2015 Mar;90(3):193-6. (PMID: 25407953)
Blood. 2012 Sep 6;120(10):2032-41. (PMID: 22493293)
Ann Hematol. 2013 Aug;92(8):1101-10. (PMID: 23558905)
Blood. 2015 Aug 6;126(6):746-56. (PMID: 26065651)
Blood. 2010 Nov 25;116(22):4439-43. (PMID: 20716774)
Blood. 2008 Feb 15;111(4):1827-33. (PMID: 18048644)
Am J Hematol. 2013 Aug;88(8):634-41. (PMID: 23620000)
Am J Clin Pathol. 2009 Dec;132(6):940-9. (PMID: 19926587)
Blood. 2011 May 12;117(19):5261-3. (PMID: 21403127)
Clin Adv Hematol Oncol. 2010 Mar;8(3):168-71. (PMID: 20400931)
Neoplasma. 2001;48(3):182-7. (PMID: 11583286)
Eur J Haematol. 1988 Mar;40(3):250-5. (PMID: 3281860)
Lancet Oncol. 2015 Jan;16(1):57-66. (PMID: 25524800)
J Clin Oncol. 2010 Aug 20;28(24):3880-9. (PMID: 20660823)

Keywords: Acute lymphoblastic leukemia; CD20; Immunophenotypic markers; TdT

Date Created: 20160116 Date Completed: 20160115 Latest Revision: 20200930

20240628

PMC4705048

10.5045/br.2015.50.4.227

26770950